EQS-News: Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates
EQS-News: Eckert Ziegler Strahlen- und Medizintechnik AG
/ Key word(s): Contract/Alliance
Berlin, Germany and Cambridge, Mass., – 8 January 2024 – Eckert Ziegler (ISIN DE0005659700, SDAX) and ARTBIO, Inc. (ARTBIO), a clinical-stage biotechnology company specializing in the development of a new class of alpha radioligand therapies (ARTs), have entered into a strategic manufacturing and supply agreement. Under the collaboration Eckert Ziegler will support ARTBIO to establish manufacturing and delivery of its pipeline therapies using its proprietary AlphaDirectTM Lead-212 (Pb-212) isolation technology. The collaboration aims to expedite the development of Lead-212 based alpha radioligand therapies, starting with the clinical development of ARTBIO’s lead asset of AB001 in prostate cancer. Initially focussing on the US market and utilizing Eckert Ziegler’s facilities in Boston, both companies plan to evaluate a global operations expansion at a later stage. Besides the US, Eckert Ziegler’s global CMO service network includes manufacturing sites in Berlin, Germany and Jintan, China. The radioisotope Lead-212 is an alpha precursor used as an active substance in cancer treatment. As part of a radiopharmaceutical product, the radioisotope enables precision treatment of tumor cells, while minimizing the damage to healthy adjacent tissue. With several studies ongoing, Pb-212-labeled compounds represent one of the most promising therapeutic approaches in nuclear medicine. "We are excited to collaborate with ARTBIO in this transformative venture,” stated Dr. Harald Hasselmann, CEO of Eckert Ziegler. ”By combining Eckert Ziegler's expertise in radiopharmaceutical manufacturing with ARTBIO's innovative approach to therapeutic solutions, we are poised to make substantial progress in advancing Lead-212 based alpha therapies." "We are pleased to partner with Eckert Ziegler to expand our distributed manufacturing network in order to reliably and efficiently deliver alpha radioligand therapies to patients," said Conrad Wueller, Director, Strategy and Operations at ARTBIO. "Eckert Ziegler's vast experience and global footprint in radiopharmaceutical manufacturing and distribution will be critical as we advance our pipeline and aim to get our therapeutic candidates to people who need them most." About Eckert Ziegler About ARTBIO Contact ARTBIO
08.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Eckert Ziegler Strahlen- und Medizintechnik AG |
Robert-Rössle-Str.10 | |
13125 Berlin | |
Germany | |
Phone: | +49 30 941084-138 |
Fax: | +49 30 941084-112 |
E-mail: | [email protected] |
Internet: | www.ezag.de |
ISIN: | DE0005659700 |
WKN: | 565970 |
Indices: | SDAX, |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1809641 |
End of News | EQS News Service |
|
1809641 08.01.2024 CET/CEST
Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie
Einseitige Zustimmung für Eckert & Ziegler Strahlen- und Medizintechnik AG mit mehreren Buy- und keiner Sell-Einschätzung.
Ein Kursziel von 95 € für Eckert & Ziegler Strahlen- und Medizintechnik AG deutet auf eine Verdopplung des aktuellen Kurses von 40.54 € hin.